The HMGB1 Knockout LoVo Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted polyclonal cell population in which the HMGB1 locus has been targeted in the human LoVo colorectal adenocarcinoma cell line. This heterogeneous knockout pool provides a powerful loss-of-function model to dissect HMGB1-dependent mechanisms without clonal selection biases. Researchers can utilize these polyclonal cells to study the immediate functional consequences of HMGB1 disruption in a relevant metastatic colorectal cancer background.
The LoVo host cell line was originally established from a lymph node metastasis of a colon adenocarcinoma, making it a well-characterized model of metastatic colorectal carcinoma. LoVo cells harbor mutations in key oncogenic pathways and are widely employed for studies of tumor progression, invasion, and drug resistance. Their aggressive phenotype allows robust assessment of genetic perturbations on metastatic behavior.
HMGB1 is a multifunctional protein that acts as a nuclear DNA chaperone, regulating transcription, chromatin architecture, and DNA repair. Upon active secretion or passive release, extracellular HMGB1 functions as a damage-associated molecular pattern (DAMP), engaging receptors such as RAGE and TLR4. This interaction triggers MyD88-dependent and -independent signaling cascades, leading to activation of NF-??B and MAPK pathways (including ERK1/2 and p38), which promote pro-inflammatory cytokine production (e.g., IL-6, IL-8), cell proliferation, and migration. HMGB1 is known to be transcriptionally regulated by TNF-??, IL-1??, and p53, and it physically interacts with RAGE, TLR4, TLR2, CD24, and CXCL12 to modulate immune and tumor cell responses.
In the context of LoVo colorectal cancer cells, HMGB1 knockout is expected to impair autocrine and paracrine signaling loops that drive tumor progression. Loss of HMGB1 reduces the activation of downstream targets such as NF-??B, ERK1/2, and MMP9, thereby attenuating proliferation, migration, invasion, and inflammatory gene expression. This model enables the dissection of HMGB1??s specific contributions to oncogenic signaling and the metastatic niche, providing a valuable tool to identify novel therapeutic vulnerabilities.
Typical research applications include investigating HMGB1-mediated colorectal cancer progression, inflammation, and immune evasion using assays such as Western blot, RT-qPCR, cell proliferation and migration assays, and NF-??B reporter assays. The polyclonal population is suitable for analyzing the role of HMGB1 in drug resistance, autophagy, and apoptosis, as well as for screening small-molecule inhibitors targeting the HMGB1-RAGE-TLR4 axis. Co-immunoprecipitation, ChIP, and RNA-seq experiments can further elucidate HMGB1??s interaction network and transcriptional targets. For further information or technical support, please contact Ascent Research.
